Clinical trials: Healthy Adolescents
Infections, Meningococcal
Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
The main purposes for conducting the study are firstly to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those of the…
- Trial name
- NCT02212457
- Testing
- Bexsero, Havrix, MenABCWY
- Where
- 32 sites in United States, Finland and 1 more
- Volunteers
- 1,063 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Novel 2009 Influenza H1N1
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children, adolescents, and adults.
- Trial name
- NCT00973700
- Testing
- MF59-eH1N1_f, eH1N1_f
- Where
- Costa Rica
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Immunisation, Healthy Volunteers
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents
Primary Objective: To demonstrate the non-inferiority of the seroprotection rate (serum bactericidal assay using human complement [hSBA] titer greater than or equal to [>=] 1:8) to meningococcal serogroups A, C, W, and Y…
- Trial name
- NCT04490018
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine), Meningococcal group A, C, W-135, and Y conjugate vaccine, Human Papillomavirus 9-valent Vaccine (9vHPV)
- Where
- 23 sites in Hungary, Italy and 2 more
- Volunteers
- 463 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder
The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 15-16 years who were vaccinated with Engerix™-B Kinder in infancy.
- Trial name
- NCT01847430
- Testing
- Engerix™-B Kinder
- Where
- 10 sites in Germany
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance-related Disorders, Alcohol-Related Disorders
LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School
LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.
- Conditions
- Substance-related Disorders, Alcohol-Related Disorders, Tobacco Use Disorder, Marijuana Use
- Trial name
- NCT07655609
- Testing
- Introduction, Norms re: Protective Behavior Strategies (PBS), Life Skills
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Prevention Strategies, LLC
Tuberculosis
Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
The purpose of this study is to evaluate safety, immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in BCG-vaccinated QFT-negative healthy adolescent.
- Trial name
- NCT03806699
- Testing
- ID93+GLA-SE
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
Infections, Meningococcal
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612
This study will demonstrate the non-inferiority of GSK Biologicals' meningococcal vaccine 134612 when given in an experimental co-administration versus vaccine 134612 alone and versus the experimental co-administration alone in…
- Trial name
- NCT00465816
- Testing
- Nimenrix (Meningococcal vaccine 134612), Twinrix
- Where
- 6 sites in Denmark, Sweden
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy Controls
Normative Data of Brain Network Activation in Adolescents and Young Adults
Establish normative data of ElMindA's Brain Network Activation (BNA) using evoked response in two age groups: adolescents and young adults.
- Trial name
- NCT01460394
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is…
- Trial name
- NCT00652938
- Testing
- HPV Vaccine (GSK580299) Cervarix TM, Engerix B
- Where
- 7 sites in Netherlands, Sweden
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Diphtheria
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US).
- Conditions
- Tetanus, Diphtheria, Pertussis, Whooping Cough
- Trial name
- NCT02587520
- Testing
- Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
- Where
- 20 sites in United States
- Volunteers
- 1,363 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- TeenCove (NCT04649151)
- Testing
- mRNA-1273, mRNA-1273.222
- Where
- 53 sites in United States, Dominican Republic
- Volunteers
- 4,328 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Prevention of Meningococcal Disease
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to…
- Trial name
- NCT00262041
- Testing
- MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY-CRM conjugate vaccine, unadjuvanted, MenACWY polysaccharide vaccine
- Where
- 3 sites in United States
- Volunteers
- 524 people
- Sponsor
- Novartis Vaccines
Infections, Papillomavirus
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
The purpose of this study is to establish the long-term persistence of the immune response and safety of the HPV vaccine in healthy females who were aged 9 to 25 years in the primary study (NCT00541970).
- Trial name
- NCT02100618
- Testing
- Blood sampling
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.
Multicentric study, Phase III; this study is a randomized, participant- and observer-blind, parallel group evaluation to evaluate the immunogenicity, relative efficacy, safety and reactogenicity of a recombinant quadrivalent…
- Trial name
- NCT03460743
- Testing
- Study group - quadrivalent recombinant hemagglutinin influenza vaccine, Control group - quadrivalent inactivated influenza vaccine
- Where
- 11 sites in Mexico
- Volunteers
- 1,556 people, healthy volunteers welcome
- Sponsor
- Laboratorios Liomont
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of immunogenicity and safety.
- Trial name
- NCT00976469
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated), Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011
- Where
- 6 sites in Austria, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Meningitis, Meningococcal
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents
The purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.
- Trial name
- NCT00808028
- Testing
- meningococcal B rLP2086 vaccine.
- Where
- 27 sites in Australia, Poland and 1 more
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis A Vaccine
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)
The objective of this study is to evaluate the safety and immunogenicity after one primary dose and one additional dose (administered twice at an interval of 6 months) of inactivated hepatitis A vaccine are administered in…
- Trial name
- NCT03654677
- Testing
- inactivated hepatitis A vaccine, Havrix Inj
- Where
- 12 sites in South Korea
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Infections, Meningococcal
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
The purpose of this study is to evaluate the long-term antibody persistence from 6, 7, 8, 9 to 10 years post-administration of MenACWY-TT conjugate vaccine as compared to Mencevax ACWY when given to healthy subjects 11 to 55…
- Trial name
- NCT01934140
- Testing
- Meningococcal vaccine GSK134612
- Where
- 2 sites in Philippines
- Volunteers
- 311 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Papillomavirus
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
The purpose of this phase IIB MedImmune-sponsored study was to evaluate the efficacy of the HPV-16/18 VLP vaccine in the prevention of infection with HPV-16 and/or HPV-18 in adolescent and young adult women.
- Trial name
- NCT00689741
- Testing
- Cervarix
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline